Request Demo
Last update 08 May 2025
Semaglutide(Hybio)
Last update 08 May 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms 司美格鲁肽注射液 |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Semaglutide(Hybio)CTR20243084
一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病患者中比较HY310注射液与诺和泰®治疗32周的疗效和安全性的多中心、随机、开放设计的Ⅲ期临床研究
[Translation] A multicenter, randomized, open-label Phase III clinical study comparing the efficacy and safety of HY310 injection and Novotec® for 32 weeks in patients with type 2 diabetes who have poor glycemic control on metformin monotherapy
ACTRN12623001277639
Evaluating the efficacy of REducing cardiometabolic risk with SEmaglutide by measuring arterial stiffness in overweight and obese adults aged over 25 with Type 1 diabetes
CTR20234315
司美格鲁肽注射液在中国健康成年受试者中的单中心、随机、开放、单次空腹皮下注射给药、两制剂、平行设计的药代动力学比对研究
[Translation] A single-center, randomized, open-label, single fasting subcutaneous injection pharmacokinetic comparison study of semaglutide injection in healthy Chinese adult subjects using two formulations and parallel design
100 Clinical Results associated with Semaglutide(Hybio)
Login to view more data
100 Translational Medicine associated with Semaglutide(Hybio)
Login to view more data
100 Patents (Medical) associated with Semaglutide(Hybio)
Login to view more data
100 Deals associated with Semaglutide(Hybio)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 3 | China | 02 Sep 2024 | |
| Diabetes Mellitus, Type 2 | Phase 3 | China | 24 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | 256 | awteiwsoxv(akjipwbalx) = ubxvcjocbg ceihhbzmfz (ltkpeszvgm ) View more | - | 23 Jun 2023 | ||
awteiwsoxv(akjipwbalx) = pczouwiigr ceihhbzmfz (ltkpeszvgm ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free